#larotrectinib

The Food and Drug Administration may approve the next site-agnostic treatment in August.

The FDA recently approved Vitrakvi for all cancers with specific gene mutation.

New drug Vitrakvi targets specific receptor kinase that promotes tumors.

TRK inhibitor larotrectinib led to durable response in adults and children with 17 cancer types.

Larotrectinib and entrectinib are effective against cancer with specific genetic changes anywhere in the body.

TRK fusions occur in less than 1 percent of cancers—but when treated with larotrectinib, patients have seen dramatic results.

World’s largest cancer conference covers all aspects of treatment, care and survivorship.

LOXO-292 demonstrates durable antitumor activity in people with lung, thyroid and other cancers with RET mutations.

In three trials larotrectinib shrank tumors in many people whose tumors overexpressed TRK fusion proteins.

New therapies target similar tumors wherever they appear.

New treatment approaches target tumors with shared characteristics, regardless of where they appear in the body.

76 percent of patients with 17 different cancers responded to “site agnostic” therapy.